CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Madrigal Pharmaceuticals, Inc. - MDGL CFD

236.12
0.52%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.97
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026346 %
Charges from full value of position ($-5.01)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026346%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004124 %
Charges from full value of position ($0.78)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Madrigal Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 234.91
Open* 236.91
1-Year Change* 226.28%
Day's Range* 233.18 - 243.65
52 wk Range 57.21-322.67
Average Volume (10 days) 490.55K
Average Volume (3 months) 9.70M
Market Cap 3.72B
P/E Ratio -100.00K
Shares Outstanding 19.74M
Revenue N/A
EPS -19.24
Dividend (Yield %) N/A
Beta -0.50
Next Earnings Date Feb 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 5, 2023 234.91 14.05 6.36% 220.86 236.79 219.89
Dec 4, 2023 221.32 13.68 6.59% 207.64 221.77 207.64
Dec 1, 2023 212.98 11.45 5.68% 201.53 213.11 195.87
Nov 30, 2023 203.12 2.30 1.15% 200.82 208.29 199.98
Nov 29, 2023 197.23 5.50 2.87% 191.73 200.05 189.12
Nov 28, 2023 190.81 -2.86 -1.48% 193.67 195.41 187.38
Nov 27, 2023 196.93 4.95 2.58% 191.98 197.61 190.40
Nov 24, 2023 194.32 8.17 4.39% 186.15 200.25 186.15
Nov 22, 2023 190.09 -2.15 -1.12% 192.24 195.94 186.13
Nov 21, 2023 188.22 3.45 1.87% 184.77 190.55 181.60
Nov 20, 2023 189.71 13.81 7.85% 175.90 190.52 174.89
Nov 17, 2023 176.53 6.64 3.91% 169.89 176.68 164.94
Nov 16, 2023 168.50 1.61 0.96% 166.89 170.48 159.89
Nov 15, 2023 161.55 5.65 3.62% 155.90 174.79 154.91
Nov 14, 2023 156.37 2.91 1.90% 153.46 156.62 150.24
Nov 13, 2023 145.91 9.99 7.35% 135.92 146.69 135.01
Nov 10, 2023 138.51 1.60 1.17% 136.91 138.82 134.81
Nov 9, 2023 136.25 -7.16 -4.99% 143.41 144.17 133.73
Nov 8, 2023 143.21 -6.69 -4.46% 149.90 151.57 142.06
Nov 7, 2023 151.92 5.02 3.42% 146.90 153.90 145.46

Madrigal Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Wednesday, February 21, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Madrigal Pharmaceuticals Inc Earnings Release
Q4 2023 Madrigal Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Total Operating Expense 293.571 242.482 206.673 94.972 40.682
Selling/General/Admin. Expenses, Total 48.13 37.318 21.864 22.648 15.293
Research & Development 245.441 205.164 184.809 72.324 25.389
Operating Income -293.571 -242.482 -206.673 -94.972 -40.682
Interest Income (Expense), Net Non-Operating -1.779 0.363 4.329 11.024 7.671
Net Income Before Taxes -295.35 -241.846 -202.244 -83.948 -32.811
Net Income After Taxes -295.35 -241.846 -202.244 -83.948 -32.811
Net Income Before Extra. Items -295.35 -241.846 -202.244 -83.948 -32.811
Net Income -295.35 -241.846 -202.244 -83.948 -32.811
Income Available to Common Excl. Extra. Items -295.35 -241.846 -202.244 -83.948 -32.811
Income Available to Common Incl. Extra. Items -295.35 -241.846 -202.244 -83.948 -32.811
Diluted Net Income -295.35 -241.846 -202.244 -83.948 -32.811
Diluted Weighted Average Shares 17.1372 16.5352 15.4466 15.3947 14.7967
Diluted EPS Excluding Extraordinary Items -17.2344 -14.6261 -13.0931 -5.45306 -2.21745
Diluted Normalized EPS -17.2344 -14.6261 -13.0931 -5.45306 -2.21745
Other, Net 0 0.273 0.1 0 0.2
Total Extraordinary Items 0 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Total Operating Expense 86.45 78.336 85.299 80.412 70.273
Selling/General/Admin. Expenses, Total 17.845 16.182 14.557 12.141 11.774
Research & Development 68.605 62.154 70.742 68.271 58.499
Operating Income -86.45 -78.336 -85.299 -80.412 -70.273
Interest Income (Expense), Net Non-Operating 0.65 1.44 -0.606 -0.785 -0.457
Other, Net 0 0 0
Net Income Before Taxes -85.8 -76.896 -85.905 -81.197 -70.73
Net Income After Taxes -85.8 -76.896 -85.905 -81.197 -70.73
Net Income Before Extra. Items -85.8 -76.896 -85.905 -81.197 -70.73
Net Income -85.8 -76.896 -85.905 -81.197 -70.73
Income Available to Common Excl. Extra. Items -85.8 -76.896 -85.905 -81.197 -70.73
Income Available to Common Incl. Extra. Items -85.8 -76.896 -85.905 -81.197 -70.73
Diluted Net Income -85.8 -76.896 -85.905 -81.197 -70.73
Diluted Weighted Average Shares 18.3109 18.1879 17.2386 17.1034 17.1034
Diluted EPS Excluding Extraordinary Items -4.68572 -4.22786 -4.98329 -4.74742 -4.13544
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -4.68572 -4.22786 -4.98329 -4.74742 -4.13544
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 361.369 271.684 285.163 440.197 485.201
Cash and Short Term Investments 358.774 270.346 284.149 439.045 483.718
Cash & Equivalents 331.549 36.269 54.004 46.697 57.379
Short Term Investments 27.225 234.077 230.145 392.348 426.339
Total Receivables, Net
Prepaid Expenses 2.595 1.338 1.014 1.152 1.483
Total Assets 362.572 273.332 286.995 442.056 485.428
Property/Plant/Equipment, Total - Net 1.203 1.648 1.832 1.859 0.227
Total Current Liabilities 115.894 76.838 46.557 25.13 8.444
Accounts Payable 23.831 21.38 1.017 1.178 2.487
Accrued Expenses 92.063 55.458 45.54 23.952 5.957
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total
Total Liabilities 165.183 77.225 47.025 25.491 8.444
Total Long Term Debt 49.289 0 0 0 0
Total Equity 197.389 196.107 239.97 416.565 476.984
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.002 0.002 0.002 0.002 0.002
Additional Paid-In Capital 1160.08 863.495 665.385 639.567 616.573
Retained Earnings (Accumulated Deficit) -962.66 -667.31 -425.464 -223.22 -139.272
Other Equity, Total -0.032 -0.08 0.047 0.216 -0.319
Total Liabilities & Shareholders’ Equity 362.572 273.332 286.995 442.056 485.428
Total Common Shares Outstanding 18.1025 17.1034 15.5082 15.4291 15.409
Other Liabilities, Total 0 0.387 0.468 0.361
Long Term Debt 49.289
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 235.469 301.595 331.284 361.369 157.112
Cash and Short Term Investments 232.351 298.418 329.477 358.774 153.192
Cash & Equivalents 51.385 77.196 113.308 331.549 41.112
Short Term Investments 170.296 221.222 216.169 27.225 93.852
Prepaid Expenses 3.118 3.177 1.807 2.595 3.92
Total Assets 237.964 302.461 332.449 362.572 158.644
Property/Plant/Equipment, Total - Net 2.495 0.866 1.165 1.203 1.532
Total Current Liabilities 99.665 99.706 98.348 115.894 98.92
Accounts Payable 16.542 17.534 12.128 23.831 18.562
Accrued Expenses 83.123 82.172 86.22 92.063 80.358
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 215.715 198.955 182.313 165.183 147.974
Total Long Term Debt 114.727 99.249 83.965 49.289 48.983
Other Liabilities, Total 1.323 0 0.071
Total Equity 22.249 103.506 150.136 197.389 10.67
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.002 0.002 0.002 0.002 0.002
Additional Paid-In Capital 1246.39 1228.95 1189.78 1160.08 887.66
Retained Earnings (Accumulated Deficit) -1224.1 -1125.36 -1039.56 -962.66 -876.755
Other Equity, Total -0.042 -0.089 -0.086 -0.032 -0.237
Total Liabilities & Shareholders’ Equity 237.964 302.461 332.449 362.572 158.644
Total Common Shares Outstanding 18.4942 18.459 18.2831 18.1025 17.1034
Cash 10.67 18.228
Long Term Debt 114.727 99.249 83.965 49.289 48.983
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -295.35 -241.846 -202.244 -83.948 -32.811
Cash From Operating Activities -224.857 -183.917 -157.561 -41.624 -25.507
Cash From Operating Activities 0.467 0.405 0.471 0.112 0.096
Non-Cash Items 32.422 26.873 20.73 22.759 13.489
Changes in Working Capital 37.604 30.651 23.482 19.453 -6.281
Cash From Investing Activities 206.686 -5.055 159.78 30.707 -380.076
Capital Expenditures -0.217 -0.209 -0.334 -0.172 -0.022
Other Investing Cash Flow Items, Total 206.903 -4.846 160.114 30.879 -380.054
Cash From Financing Activities 313.451 171.237 5.088 0.235 314.335
Financing Cash Flow Items -0.886 0
Issuance (Retirement) of Stock, Net 264.337 171.237 5.088 0.235 314.335
Net Change in Cash 295.28 -17.735 7.307 -10.682 -91.248
Issuance (Retirement) of Debt, Net 50
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -76.896 -295.35 -209.445 -128.248 -57.518
Cash From Operating Activities -84.067 -224.857 -166.342 -107.273 -49.913
Cash From Operating Activities 0.124 0.467 0.338 0.217 0.107
Non-Cash Items 11.683 32.422 24.034 15.599 7.477
Changes in Working Capital -18.978 37.604 18.731 5.159 0.021
Cash From Investing Activities -186.864 206.686 140.299 75.162 55.926
Capital Expenditures -0.035 -0.217 -0.188 -0.155 -0.052
Other Investing Cash Flow Items, Total -186.829 206.903 140.487 75.317 55.978
Cash From Financing Activities 52.69 313.451 49.114 49.114 0
Issuance (Retirement) of Stock, Net 17.903 264.337 0 0 0
Net Change in Cash -218.241 295.28 23.071 17.003 6.013
Financing Cash Flow Items -0.213 -0.886 -0.886 -0.886
Issuance (Retirement) of Debt, Net 35 50 50 50
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Janus Henderson Investors Investment Advisor/Hedge Fund 15.4394 3042661 1558535 2023-09-29 LOW
Baker Bros. Advisors LP Hedge Fund 7.8404 1545113 0 2023-10-03 LOW
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 7.6883 1515151 -151515 2023-06-30 LOW
Bay City Capital L.L.C. Venture Capital 7.6712 1511782 0 2023-03-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.4237 1462998 47070 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.7127 928734 78587 2023-06-30 LOW
SQN, L.L.C. Corporation 3.3264 655540 0 2023-03-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.7592 543759 23945 2023-06-30 LOW
Craves (Frederick B) Individual Investor 2.3877 470556 1198 2023-06-15 LOW
Assenagon Asset Management S.A. Investment Advisor 2.3685 466766 -49822 2023-06-30 HIGH
Marshall Wace LLP Investment Advisor/Hedge Fund 2.3374 460644 -81120 2023-06-30 HIGH
Taub (Rebecca A) Individual Investor 2.2061 434758 -20001 2023-03-31 LOW
AllianceBernstein L.P. Investment Advisor/Hedge Fund 1.8832 371116 347448 2023-06-30 LOW
Paulson & Co. Inc. Hedge Fund 1.777 350200 350200 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 1.7704 348887 86654 2023-06-30 LOW
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 1.6317 321569 142579 2023-06-30 LOW
Perceptive Advisors LLC Private Equity 1.5374 302987 -347575 2023-06-30 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.3768 271319 23262 2023-06-30 LOW
Artisan Partners Limited Partnership Investment Advisor 1.1675 230090 14320 2023-06-30 LOW
RTW Investments L.P. Investment Advisor/Hedge Fund 1.1243 221562 221562 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Madrigal Pharmaceuticals, Inc. Company profile

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The Company’s lead product candidate, MGL-3196 (resmetirom), is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of non-alcoholic steatohepatitis (NASH)and heterozygous familial hypercholesterolemia (HeFH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and HeFH.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Madrigal Pharmaceuticals Inc revenues was not reported. Net loss increased 20% to $241.8M. Higher net loss reflects R & D increase of 11% to $194.5M (expense), G & A increase from $10M to $21.1M (expense), Stock-based Compensation in SGA increase of 36% to $16.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$13.09 to -$14.63.

Equity composition

Common Stock $.0001 Par, 10/10, 100M auth., 42,166,779 issd. Insiders control approx. 37.8%. IPO: 2/06/07, 5M shares @ $10 per share by Bear, Stearns & Co. Inc.

Industry: Bio Therapeutic Drugs

200 Barr Harbor Dr Ste 400
WEST CONSHOHOCKEN
PENNSYLVANIA 19428-2978
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

Gold

2,028.26 Price
+0.370% 1D Chg, %
Long position overnight fee -0.0196%
Short position overnight fee 0.0114%
Overnight fee time 22:00 (UTC)
Spread 0.30

BTC/USD

43,922.25 Price
-0.160% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

15,800.20 Price
-0.510% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 22:00 (UTC)
Spread 1.8

XRP/USD

0.64 Price
+2.700% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading